Viatris hosts r&d event focusing on its collaboration with idorsia, phase 3 assets selatogrel and cenerimod and key elements of its pipeline

Pittsburgh , march 27, 2024 /prnewswire/ -- at a meeting with the investment community today, viatris inc. (nasdaq: vtrs), a global healthcare company, will outline how it is continuing to evolve its r&d strategy to deliver on its goal of building a more durable, higher-margin portfolio of patented innovation on the foundation of its strong base business. the focus of the event will be a discussion of its collaboration with idorsia, phase 3 assets selatogrel and cenerimod and key elements of the company's pipeline.
VTRS Ratings Summary
VTRS Quant Ranking